Macrophage, the potential key mediator in CAR-T related CRS
Abstract Chimeric antigen receptor (CAR) T cell therapy is a new frontier in cancer therapy. The toxicity of cytokine release syndrome (CRS) has become one of the major challenges that limits the wider use of CAR T cells to fight cancer. Exploration of CRS pathogenesis and treatment is becoming the...
Main Authors: | Zhaonian Hao, Ruyuan Li, Li Meng, Zhiqiang Han, Zhenya Hong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40164-020-00171-5 |
Similar Items
-
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
by: Chittepu, V.C.S.R, et al.
Published: (2022) -
Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
by: Si S, et al.
Published: (2020-08-01) -
Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
by: Monica S. Thakar, et al.
Published: (2020-01-01) -
Cytokine Release Syndrome: Current Perspectives
by: Murthy H, et al.
Published: (2019-10-01) -
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
by: Luis Gerardo Rodríguez-Lobato, et al.
Published: (2020-07-01)